Mucopolysaccharidoses – Epidemiology – Mature Markets

Clarivate Epidemiology’s coverage of mucopolysaccharidoses (MPS) comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom and Japan). We report the prevalence of MPS for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.

Clarivate Epidemiology’s MPS forecast will answer the following question:

  • How will demographic trends, such as changes in birth rates, affect the epidemiology of MPS over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts seven MPS patient populations, as follows:

  • Diagnosed prevalent cases of MPS.
  • Diagnosed prevalent cases of MPS I.
  • Diagnosed prevalent cases of MPS II.
  • Diagnosed prevalent cases of MPS III.
  • Diagnosed prevalent cases of MPS IV.
  • Diagnosed prevalent cases of MPS VI.
  • Diagnosed prevalent cases of MPS VII.

Note: Coverage may vary by country.